Argininamide Stabilized Antibody Formulation for Photostress
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Highly-concentrated antibody solutions for subcutaneous injection face challenges with viscosity and stability, particularly during storage and exposure to light, leading to protein aggregation and degradation.
Innovation Solution
Incorporating argininamide, arginine ethyl ester, or valinamide as stabilizing agents in protein formulations at concentrations between 50 mM to 200 mM, along with histidine or citrate buffers, to suppress protein aggregation and destabilization caused by photostress.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If highly-concentrated antibody solutions are prepared for subcutaneous injection, then the injection volume is reduced and dosing efficiency is improved, but the solutions become highly viscous and prone to aggregation during storage
Solution Approach 1:
The patent applies parameter changes by systematically optimizing multiple formulation parameters including amino acid concentration (10-500 mM), buffer composition, pH (4.5-7.5), and excipient ratios to achieve the optimal balance between high antibody concentration and formulation stability. This multi-parameter optimization enables maintaining dosing efficiency while preventing aggregation during storage
Solution Approach 2:
The patent employs composite materials by combining antibodies with multiple stabilizing components including amino acids (arginine, glycine, alanine), buffers (phosphate, citrate, acetate), and excipients (sugars, polyols) to create a composite formulation system that simultaneously provides high concentration capability and enhanced stability against aggregation
2Stability of the object's composition
If arginine is used as a stabilizing agent in highly-concentrated antibody formulations, then protein stability is improved and viscosity is reduced, but the formulation remains vulnerable to photostress-induced aggregation
Solution Approach 1:
The patent merges multiple stabilizing agents including arginine (10-500 mM) with photoprotective compounds such as antioxidants (ascorbic acid, tocopherol), UV absorbers (benzophenone derivatives), and metal chelators (EDTA at 0.1-50 mM) to create a multi-functional stabilization system that simultaneously addresses protein stability and photostress protection
Solution Approach 2:
The patent introduces intermediary substances that mediate between light energy and protein molecules, including UV-absorbing excipients that intercept photonic energy before it reaches the antibody, and antioxidant intermediaries that scavenge reactive oxygen species generated by photostress, thereby preventing direct light-induced aggregation
3Stability of the object's composition
If lyophilization is used to prepare highly-concentrated formulations, then stability during storage is improved, but the viscosity of redissolved formulations increases and handling becomes more difficult
Solution Approach 1:
The patent applies preliminary action by incorporating stabilizing agents and protective excipients into the formulation before any stress conditions occur, creating a pre-stabilized system that maintains stability during storage without requiring lyophilization, thereby enabling direct use as liquid formulations that are easier to handle and administer
Data Source
AI summary
Addition of argininamide or valinamide to a highly concentrated antibody solution was found to lead to remarkable stabilization, in particular, stabilization against photostress.